TA方案和NP方案治疗晚期乳腺癌临床研究

Clinical Review of TA and NP in Treatment of Advanced Breast Cancer

目的：观察比较紫衫醇＋表阿霉素（TA）和长春瑞滨＋顺铂（NP）两种化疗方案治疗晚期乳腺癌的疗效和毒性.方法：46例晚期乳腺癌患者随机分为TA组和NP组,每组23例.TA组紫杉醇135 mg/m^2,第1天;表阿霉素25 mg/m^2 ,第2～3天.NP组长春瑞滨40 mg/m^2,第1天、第8天;顺铂25 mg/m^2, 第1～4天. 结果：疗效按WHO标准,TA组总有效率65.2%,NP组总有效率为56.5%,两组间比较差异无统计学意义（P＞0.05）.主要毒副反应中,骨髓抑制、恶心呕吐、脱发,两组间差异无统计学意义（P＞0.05）;TA组的关节肌肉酸痛发生率（39.1%）高于NP组（4.3%）,NP组的静脉炎发生率（43.5%）,明显高于TA组（8.7%）,组间比较均有统计学意义 （P＜0.05）.结论：TA和NP两组方案治疗复发转移性乳腺癌疗效高且无统计学差别,均可作为治疗晚期乳腺癌的有效方案.

Objective：To evaluate the efficacy and toxicity of TA and NP in the treatment of advanced breast cancer. Methods： Forty - six patients were allocated to the TA group （ pacfitaxel ＋ Epirubiei ） and the NP group （vinorelbine ＋ cisplatin）. 23 patients received TA（ PTX 135 mg/m^2 on day 1 plus DDP 25 mg/m^2 on days 1 -2） ;23 patients received NP （vinorelbine 40mg/m^2 on days 1 ,days 8 ,cisplatin 25 mg/m^2 on daysl -3）. Results：In TA group,the response rate was 65.2%. In NP group,the response rate was 56.5%. The efficacy was not significantly different between the two groups（ P 〉 0.05 ）. The main toxicity was not significantly different between the two groups（P 〉 0.05） , include leukopenia,gastroenteric reaction and alopecia, but TA group（ 39. 1% ） was higher than the NP group （4.3%） in muscle and skeletal pain. There were significant difference between the two groups（P 〈 0.05） ;NP group（43.5% ） was higher than the TA group（8.7% ） in phlebitis. There were significant difference between the two groups （ P 〈 0.05 ）. Conclusions： Both therapies are effective for advanced breast cancer and the response rate is no significant difference.